Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month

by | Apr 21, 2026 | General

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Kiniksa Pharmaceuticals Internationl PLC (NASDAQ:KNSA)

  • On April 16, Wedbush analyst David Nierengarten maintained Kiniksa Pharmaceuticals with an Outperform rating and raised the price target from $53 to $58. The company’s stock fell around 10% over the past five days and has a 52-week low of $19.62.
  • RSI Value: 28
  • KNSA Price Action: Shares of Kiniksa Pharmaceuticals fell 5.4% to close at $42.46 on Monday.
  • Edge Stock Ratings: 86.15 Momentum score with Value at 49.18.

Nano-X Imaging Ltd (NASDAQ:NNOX)

  • On April 20, Nano-X Imaging reported worse-than-expected fourth-quarter sales results. “The fourth quarter of 2025 was marked by strong momentum across all Nanox business segments, particularly good commercial progress in the U.S. market,” said Erez Meltzer, Nanox Chief Executive Officer and acting Chairman of the Board of Directors. The company’s stock fell around 12% over the past five days and has a 52-week low of $2.11.
  • RSI Value: 28.2
  • NNOX Price Action: Shares of Nano-X Imaging fell 24.4% to close at $2.16 on Monday.
  • Benzinga Pro’s charting tool helped identify the trend in NNOX stock.

Atrium Therapeutics Inc (NASDAQ:RNA)

  • On April 20, Atrium Therapeutics announced inducement grants under Nasdaq Listing Rule 5635(c)(4). The company’s stock fell around 3% year-to-date and has a 52-week low of $11.95.
  • RSI Value: 28.4
  • RNA Price Action: Shares of Atrium Therapeutics fell 0.8% to close at $14.30 on Monday.
  • Benzinga Pro’s signals feature notified of a potential breakout in RNA shares.

Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and see how they compare.

Photo via Shutterstock